1-20 of 76
Razelle Kurzrock
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies

Benedito A. Carneiro, Ludimila Cavalcante, Devalingam Mahalingam, Anwaar Saeed, Howard Safran, Wen Wee Ma, Andrew L. Coveler, Steven Powell, Bruno Bastos, Elizabeth Davis, Vaibhav Sahai, William Mikrut, James Longstreth, Sheri Smith, Taylor Weiskittel, Hu Li, Brittany A. Borden, R. Donald Harvey, Solmaz Sahebjam, Andres Cervantes, Austin Koukol, Andrew P. Mazar, Neeltje Steeghs, Razelle Kurzrock, Francis J. Giles, Pamela Munster
Journal: Clinical Cancer Research
Clin Cancer Res (2023)
https://doi.org/10.1158/1078-0432.CCR-23-1916
Published: 20 November 2023
View article titled, Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies
Open the PDF for Phase 1 study of Elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, as monotherapy or combined with chemotherapy in patients with advanced malignancies in another window
Includes: Supplementary data
Journal Articles

A phase II basket trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia

Sandip P. Patel, Megan Othus, Young Kwang Chae, Michael J. Dennis, Sarah Gordon, David Mutch, Wolfram Samlowski, William R. Robinson, Elad Sharon, Christopher Ryan, Gabby Lopez, Melissa Plets, Charles Blanke, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2023)
https://doi.org/10.1158/1078-0432.CCR-23-2293
Published: 26 October 2023
View article titled, A phase II basket trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia
Open the PDF for A phase II basket trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia in another window
Includes: Supplementary data
Journal Articles

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze, Mary D. Chamberlin, Barbara J. Haley, Anna Maria V. Storniolo, Mridula P. Reddy, Scott A. Anderson, Collin T. Zimmerman, Anne P. O'Dea, Hamid R. Mirshahidi, Jordi Rodon Ahnert, Frank J. Brescia, Olwen Hahn, Jane M. Raymond, David D. Biggs, Roisin M. Connolly, Elad Sharon, Larissa A. Korde, Robert J. Gray, Edward Mayerson, Melissa Plets, Charles D. Blanke, Young Kwang Chae, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (2): 271–278.
https://doi.org/10.1158/1078-0432.CCR-21-2182
Published: 19 January 2022
View article titled, A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)
Open the PDF for A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609) in another window
Includes: Supplementary data
Journal Articles

Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response

Mayra Yebra, Shruti Bhargava, Avi Kumar, Adam M. Burgoyne, Chih-Min Tang, Hyunho Yoon, Sudeep Banerjee, Joseph Aguilera, Thekla Cordes, Vipul Sheth, Sangkyu Noh, Rowan Ustoy, Sam Li, Sunil J. Advani, Christopher L. Corless, Michael C. Heinrich, Razelle Kurzrock, Scott M. Lippman, Paul T. Fanta, Olivier Harismendy, Christian Metallo, Jason K. Sicklick
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (1): 187–200.
https://doi.org/10.1158/1078-0432.CCR-21-2092
Published: 05 January 2022
View article titled, Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response
Open the PDF for Establishment of Patient-Derived Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response in another window
Includes: Supplementary data
Journal Articles

Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics

Shumei Kato, Jacob J. Adashek, Justin Shaya, Ryosuke Okamura, Rebecca E. Jimenez, Suzanna Lee, Jason K. Sicklick, Razelle Kurzrock
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (10): 2792–2797.
https://doi.org/10.1158/1078-0432.CCR-20-3761
Published: 15 May 2021
View article titled, Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics
Open the PDF for Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics in another window
Includes: Supplementary data
Journal Articles

Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma

Filip Janku, Haeseong Park, S. Greg Call, Kiran Madwani, Yasuhiro Oki, Vivek Subbiah, David S. Hong, Aung Naing, Vivianne M. Velez-Bravo, Tamara G. Barnes, Fredrick B. Hagemeister, Gerald S. Falchook, Daniel D. Karp, Jennifer J. Wheler, Sarina A. Piha-Paul, Ignacio Garrido-Laguna, Elizabeth J. Shpall, Luis E. Fayad, Sattva S. Neelapu, Funda Meric-Bernstam, Razelle Kurzrock, Michelle A. Fanale
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (21): 5579–5587.
https://doi.org/10.1158/1078-0432.CCR-20-1215
Published: 02 November 2020
View article titled, Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma
Open the PDF for Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Abstract 43: Clinical implications of real-world data on plasma circulating tumor DNA in gynecologic cancer patients

Lindsey Michelle Charo, Ramez N. Eskander, Ryosuke Okamura, Sandip Patel, Mina Nikanjam, Richard Layman, David E. Piccioni, Shamei Kato, Michael McHale, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_1): 43.
https://doi.org/10.1158/1557-3265.ADVPRECMED20-43
Published: 15 June 2020
View article titled, Abstract 43: Clinical implications of real-world data on plasma circulating tumor DNA in gynecologic cancer patients
Journal Articles

Abstract IA15: Liquid biopsies: Implications for therapeutic response/resistance and prognosis

Razelle Kurzrock, Shumei Kato
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): IA15.
https://doi.org/10.1158/1557-3265.LiqBiop20-IA15
Published: 01 June 2020
View article titled, Abstract IA15: Liquid biopsies: Implications for therapeutic response/resistance and prognosis
Journal Articles

Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine—Response

Sandip P. Patel, Megan Othus, Young Kwang Chae, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2434.
https://doi.org/10.1158/1078-0432.CCR-20-0790
Published: 15 May 2020
View article titled, Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine—Response
Open the PDF for Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine—Response in another window
Journal Articles

A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors

Sandip P. Patel, Megan Othus, Young Kwang Chae, Francis J. Giles, Donna E. Hansel, Preet Paul Singh, Annette Fontaine, Manisha H. Shah, Anup Kasi, Tareq Al Baghdadi, Marc Matrana, Zoran Gatalica, W. Michael Korn, Jourdain Hayward, Christine McLeod, Helen X. Chen, Elad Sharon, Edward Mayerson, Christopher W. Ryan, Melissa Plets, Charles D. Blanke, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2290–2296.
https://doi.org/10.1158/1078-0432.CCR-19-3356
Published: 15 May 2020
View article titled, A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors
Open the PDF for A Phase II Basket Trial of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors in another window
Includes: Supplementary data
Journal Articles

First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors

Gerald S. Falchook, Razelle Kurzrock, Hesham M. Amin, Wenyuan Xiong, Siqing Fu, Sarina A. Piha-Paul, Filip Janku, Ghazaleh Eskandari, Daniel V. Catenacci, Manfred Klevesath, Rolf Bruns, Uz Stammberger, Andreas Johne, Friedhelm Bladt, Manja Friese-Hamim, Pascal Girard, Samer El Bawab, David S. Hong
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (6): 1237–1246.
https://doi.org/10.1158/1078-0432.CCR-19-2860
Published: 13 March 2020
View article titled, First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
Open the PDF for First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies

Gerald Falchook, Seth Rosen, Patricia LoRusso, Justin Watts, Shilpa Gupta, Catherine C. Coombs, Moshe Talpaz, Razelle Kurzrock, Monica Mita, Ryan Cassaday, Wael Harb, Julio Peguero, David C. Smith, Sarina A. Piha-Paul, Russ Szmulewitz, Marcus S. Noel, Swamy Yeleswaram, Phillip Liu, Julie Switzky, Gongfu Zhou, Fred Zheng, Amitkumar Mehta
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (6): 1247–1257.
https://doi.org/10.1158/1078-0432.CCR-18-4071
Published: 13 March 2020
View article titled, Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Open the PDF for Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies in another window
Includes: Supplementary data
Journal Articles

Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA

Ahmed O. Kaseb, Nora S. Sánchez, Shiraj Sen, Robin K. Kelley, Benjamin Tan, Andrea G. Bocobo, Kian H. Lim, Reham Abdel-Wahab, Marc Uemura, Roberto Carmagnani Pestana, Wei Qiao, Lianchun Xiao, Jeffrey Morris, Hesham M. Amin, Manal M. Hassan, Asif Rashid, Kimberly C. Banks, Richard B. Lanman, AmirAli Talasaz, Kenna R. Mills-Shaw, Bhawana George, Abedul Haque, Kanwal P.S. Raghav, Robert A. Wolff, James C. Yao, Funda Meric-Bernstam, Sadakatsu Ikeda, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (20): 6107–6118.
https://doi.org/10.1158/1078-0432.CCR-18-3341
Published: 15 October 2019
View article titled, Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA
Open the PDF for Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA in another window
Includes: Supplementary data
Journal Articles

A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers

Razelle Kurzrock, Douglas W. Ball, Marianna L. Zahurak, Barry D. Nelkin, Vivek Subbiah, Shabina Ahmed, Ashley O'Connor, Enusha Karunsena, Rose M. Parkinson, Justin A. Bishop, Yoonji Ha, Rajni Sharma, Christopher D. Gocke, Ralph Zinner, Michelle A. Rudek, Steven I. Sherman, Nilofer S. Azad
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5475–5484.
https://doi.org/10.1158/1078-0432.CCR-18-1881
Published: 13 September 2019
View article titled, A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers
Open the PDF for A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers in another window
Includes: Supplementary data
Journal Articles

Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Shumei Kato, Ryosuke Okamura, Joel M. Baumgartner, Hitendra Patel, Lawrence Leichman, Kaitlyn Kelly, Jason K. Sicklick, Paul T. Fanta, Scott M. Lippman, Razelle Kurzrock
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (24): 6248–6256.
https://doi.org/10.1158/1078-0432.CCR-18-1128
Published: 13 December 2018
View article titled, Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Open the PDF for Analysis of Circulating Tumor DNA and Clinical Correlates in Patients with Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus

Alexa B. Schrock, Dean Pavlick, Samuel J. Klempner, Jon H. Chung, Brady Forcier, Allison Welsh, Lauren Young, Bryan Leyland-Jones, Rodolfo Bordoni, Richard D. Carvajal, Joseph Chao, Razelle Kurzrock, Jason K. Sicklick, Jeffrey S. Ross, Philip J. Stephens, Craig Devoe, Fadi Braiteh, Siraj M. Ali, Vincent A. Miller
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (8): 1881–1890.
https://doi.org/10.1158/1078-0432.CCR-17-3103
Published: 12 April 2018
View article titled, Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus
Open the PDF for Hybrid Capture–Based Genomic Profiling of Circulating Tumor DNA from Patients with Advanced Cancers of the Gastrointestinal Tract or Anus in another window
Includes: Supplementary data
Journal Articles

Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors

Denis L. Jardim, Débora de Melo Gagliato, Francis J. Giles, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (8): 1785–1794.
https://doi.org/10.1158/1078-0432.CCR-17-1970
Published: 12 April 2018
View article titled, Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors
Open the PDF for Analysis of Drug Development Paradigms for Immune Checkpoint Inhibitors in another window
Includes: Supplementary data
Journal Articles

Genomics of Immunotherapy-Associated Hyperprogressors—Response

Shumei Kato, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6376.
https://doi.org/10.1158/1078-0432.CCR-17-1990
Published: 12 October 2017
View article titled, Genomics of Immunotherapy-Associated Hyperprogressors—Response
Open the PDF for Genomics of Immunotherapy-Associated Hyperprogressors—Response in another window
Journal Articles

Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy

Yulian Khagi, Aaron M. Goodman, Gregory A. Daniels, Sandip P. Patel, Assuntina G. Sacco, James M. Randall, Lyudmila A. Bazhenova, Razelle Kurzrock
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5729–5736.
https://doi.org/10.1158/1078-0432.CCR-17-1439
Published: 01 October 2017
View article titled, Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy
Open the PDF for Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based Immunotherapy in another window
Includes: Supplementary data
Journal Articles

Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma

Maria C. Schwaederlé, Sandip P. Patel, Hatim Husain, Megumi Ikeda, Richard B. Lanman, Kimberly C. Banks, AmirAli Talasaz, Lyudmila Bazhenova, Razelle Kurzrock
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (17): 5101–5111.
https://doi.org/10.1158/1078-0432.CCR-16-2497
Published: 31 August 2017
View article titled, Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma
Open the PDF for Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma in another window
Includes: Supplementary data